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OL-070 Analysis on the multi-drug resistance of
Neisseria gonorrhoeae and plasmid proﬁles
isolated from female patients
X.J. Zhan1 *, D.Z. Xie1, Y.P. Xu1, S.H. Yang1, L. Zhao2,
L.W. Tan1, X.R. Shu3. 1Detection Center, Jiangxi Institute
of Medical Science, 2Department of microbiology, Jiangxi
Institute of Medical Science, 3Department of clinical
laboratory, the Maternal and Children Health Care Hospital
of Jiangxi, China
Objective: To investigate antibiotic multi-drug resistance
of Neisseria gonorrhoeae (N. gonorrhoeae) strains isolated
from the local female patients and the role of plasmid-
mediated on resistance of N. gonorrhoeae.
Methods: Antimicrobial susceptibility of N. gonorrhoeae
to various antibiotics was analysed by K-B disk diffusion
method, and strains of multi-drug resistance were screened
out. The agar-dilution method was used to determine the
minimum inhibitory concentration (MIC) of three antibiotics
including Penicillin-G, Tetracycline, Ciproﬂoxacin. It was
also compared that MIC of three antibiotics to PPNG positive
and PPNG negative strains. Extraction and analysis of the
plasmids in 69 N. gonorrhoeae were determined by alkaline-
lysis and Sepharose electrophoresis technic.
Results: 58 multi-drug resistance strains (67.44%) were
obtained by the K-B method. There were 15 strains (17.44%)
to 4 antibiotics, 9 strains (10.47%) to 5 antibiotics, 23
strains (26.74%) to 6 antibiotics and 11 strains (12.79%) to
7 antibiotics resistance among N.gonorrhoeae strains. The
MIC90 for penicillin, tetracycline and ciproﬂoxacin to PPNG
positive strains were 64.0, 32.0, 32.0mg/ml and 8.0, 16.0,
2.0 mg/ml to negative strains, respectively. Four types of
the plasmid with 4.2Kb, 7.4Kb, 39.5Kb and 42.5Kb molecular
weighe were found among 69 N. gonorrhoeae strains. The
plasmid proﬁles types of 39.5kb (24.63%) and 39.5 + 42.5kb
(13.04%) were prominent.
Conclusion: The study showed that the mult-resistance of
N. gonorrhoeae in female patients was severe. Resistant
plasmids transfered easily among N. gonorrhoeae strains.
And the plasmids of 39.5Kb and 7.4Kb were relative with
penicillin resistance.
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Hepatitis C virus (HCV) is an important cause of liver
disease in HIV-infected patients. One-third of HIV-infected
individuals worldwide suffer from chronic hepatitis C, but
HCV affects more than 75% of HIV positive subjects infected
parenterally. The intersection of these 2 epidemics has
signiﬁcant clinical implications for both infections and their
medical consequences.
Infection with HCV is more common after exposure to
blood than by sexual transmission; thus male homosexual
with HIV infection are less lokely to be co-infected
with HCV than intravenous drug users or hemophiliacs.
Hepatitis C virus thought to be directly cytopathic, and
thus hepatic damage should not be ameliorated by HIV-
induced immunosuppression. A diagnosis of HCV infection,
the possibility of false-positive Hepatitis C virus antibody
results, especially in patients with hyperglobulinemia,
warrants the use of supplementary testing for antibody
with recombinant immunoblot as-say or direct assay of HCV
viremia with the polymerase chain reaction. A recent study
of the natural history of HCV and HIV in hemophiliacs found
that 9% of co-infected patients developed liver failure,
whereas none of the patients infected with hepatitis C
virus alone developed liver failure. Most of the patients
with liver failure had CD4 counts <100/ml although none
had progressed to AIDS. Whether the development of liver
failure was related to HIV-induced immunosuppression,
unrecognized opportunistic infection, or the adverse effects
of antiretroviral therapy was not clear.
The decision to treat hepatitis C virus-related liver disease
in patients co-infected with HIV is difﬁcult because of the
lack of controlled studies. Clinical trials have documented
the enhanced antiviral efﬁcacy of combination therapy
with ribavirin and interferon Alfa, with sustained treatment
responses ranging from 33% to 49%.
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Objectives: CDAD is a growing clinical challenge in the
USA. Emerging drug resistance is the primary cause of
treatment failure causing recurrence. Oral Vancomycin and
Metronidazole are the approved therapies. “Turmeric” has
been used over centuries in Eastern culture and medicine.
It is an antioxidant, anti-ulcerogenic, anti-inﬂammatory and
antimicrobial agent. Turmeric enema has been used in
Ulcerative colitis. This clinical trial evaluates the role of
turmeric enema in moderate to severe community acquired
CDAD.
Methods: Thirty-six patients (n = 36); mean age of 53 years
with moderate to severe CDAD were randomized into three
groups: Group A Placebo (n = 11), Group B Vancomycin
enema (n = 12), 250mgBD and Group C Turmeric enema
(n = 13), 1 gm twice daily for 10 days. All patients received
oral metronidazole 500mg thrice daily for 14 days. ATLAS
score for clinical severity, stool for C Difﬁcile toxin A/B
were measured initially and at the end of therapy. Flexible
sigmoidoscopy was performed, pre- and post-therapy after
21 days. Multivariate analysis was obtained among all the
groups with clinical score, endoscopic appearance and
cost.
Results: All patients tolerated the enemas well except
Group C with complaints of staining of fomites. 7/11 (66%) in
group A compare to 10/12 (83%) in group B, and 10/13 (76%)
in group C eradicated the infection. Groups B and C had
reduced ATLAS score and endoscopic score of 60% compared
to Group A’s 38%. The recurrence rate was lower in both
Group B 1/10 (10%) and Group C 1/11 (9%) over placebo
2/7 (29%). Post-treatment endoscopic appearance of luminal
ulcers with Vancomycin (p = 0.037) and Turmeric (p = 0.031)
compared with the Placebo had a signiﬁcant difference. Post
treatment mucosal bleeding was statistically signiﬁcant in
Turmeric (p = 0.001) to vanco (p = 0.027).
Conclusion: This study demonstrates no signiﬁcant
difference between Turmeric and Vancomycinenema in
moderate to severe CDAD. Patient tolerated both enemas
with signiﬁcant cost beneﬁt in turmeric over Vancomycin. A
larger control trial is necessary to validate the efﬁcacy.
